Reprogenetics
Experts in Preimplantation Genetic Diagnosis
Array CGH analysis: aneuploidy is not related with the number of embryos generated
Abstract This study retrospectively analysed array comparative genomic hybridization (CGH) results of 7753 embryos from 990 patients to determine the frequency of embryonic euploidy and its relationship with the cohort size (i.e. the number of embryos available for biopsy and array CGH analysis). Linear regression analysis was performed to assess the effect of cohort size on euploidy rate adjusted for the effect of female age. While increasing female age was associated with a significant decrease in euploidy rate of day-3 and day-5 embryos (P < 0.001 for both groups), cohort size was not significantly... Read→
Validation of Array Comparative Genomic Hybridization for Pre-implantation Genetic Diagnosis
Researchers at Reprogenetics have published a study demonstrating the high accuracy of a new technique, called array CGH (aCGH), for analysis and screening of all chromosomes in human embryos. The authors report that errors or potential misdiagnoses occur very rarely with this technique. In the case of individual blastomeres from day-3 embryos, the error rate is only 1.8%, despite complications arising from mosaic embryos; these are embryos with a mix of normal and abnormal cells. They are known to occur frequently in vitro and can cause non-technical diagnostic errors during PGD. Further research... Read→
Products of Conception Help Determine IVF Reponse
Reprogenetics offers Products of Conception to help couples get a better picture of how they might respond to IVF Fertility treatments. Based on a number of genetic and cytogenetic factors, Reprogenetics is able to uniquely predict IVF outcome based on the historical data of thousands of other couples who have been helped by our laboratory. Read More →
Array CGH Testing and Embryo Prognosis
Array CGH testing allows for the detection of all 24-chromosome type aneuploidies in human embryos (either by Polar Body, day 3, or blastocyst biopsy). At Reprogenetics, having performed >1,500 cases of aCGH testing allows us to provide you with the prognosis of replacing normal embryos depending on the number of embryos produced and the age of the patient. This can be handy to decide whether to recommend Preimplantation Genetic Diagnosis, egg donation, and/or help patients transition to egg donation through a PGD cycle. Day 3 Prognosis Depending on Age and Ovarian Response The... Read→
For Medical Professionals
Reprogenetics is the leader in PGD. We excel because of our extensive experience, original research, unique and diversified background of staff, the ability to provide training, availability of expert advice and access to staff 365 days a year. Reprogenetics... Read→
Research and Development
Unlike other Preimplantation Genetic Diagnosis companies, Reprogenetics does not simply copy documented procedures and apply them to IVF Patients. Reprogenetics continues to innovate in order to provide better services for our patients. Towards this end,... Read→
For Patients
This section is for current and potential patients of Reprogenetics. Here you will find information that will answer questions you may have about our services. Why choose Reprogenetics? Which test is right for us? Genetic Counseling Unlocking the... Read→